Contact Us

Gadolinium MRI/MRA Contrast Dye
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Have you had an MRI where contrast was used?

Have you been diagnosed with NSF or NFD?

Do you have Diabetes

Please describe side effects:

Did you have a prior kidney condition?

If yes please describe: 

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Magnevist Lawsuit Blames Gadolinium Contrast Dye for NSF

Jul 7, 2008 | Parker Waichman LLP A  Minnesota woman who claims she developed Nephrogenic Systemic Fibrosis (NSF) after receiving Magnevist during an MRI procedure is suing the maker of the gadolinium contrast dye.  The plaintiff in the Magnevist lawsuit is represented by the law firm of Parker Waichman LLP.

NSF is a devastating condition that affects people with pre-existing kidney problems. There is currently no cure for NSF and no one understands its specific cause. The disorder is characterized  by high blood pressure, burning, itching, swelling and hardening of the skin. Other symptoms include red or dark patches on the skin; pain deep in the hip bones or ribs and muscle weakness. NSF can progress to the point of causing severe stiffness in joints, and it can lead to death.

The evidence that gadolinium contrast agents play a role in the development of NSF is fast becoming irrefutable. Dutch scientists made the first connection between NSF and gadolinium in 2006. Since then, researchers at Yale University have reported that 95-percent of those with NSF had undergone a Magnetic Imaging Resonance (MRI) procedure that involved a gadolinium contrast dye two to three months before their symptoms appeared. Researchers at Massachusetts General Hospital also have found that kidney patients who had undergone MRIs with gadolinium  contrast dyes were 10 times more likely to develop NSF than patient who had not been exposed to such agents.

In September 2007, the Food & Drug Administration (FDA) asked the manufacturers of gadolinium contrast dyes to add a black box warning to the product labels about its association with NSF. The FDA also warned that patients with kidney disease should avoid gadolinium contrast agents.

According to the lawsuit, the plaintiff received an injection of Magnevist gadolinium contrast dye on March 23, 2001.  The Brooklyn Center, Minn. woman was diagnosed with NSF in February 2007. The lawsuit, which names Bayer-Schering and its subsidiary Berlex Laboratories as defendants, says that the plaintiff continues to  suffer from the severe, debilitating and progressive fibrotic changes associated with NSF. This has permanently disabled, disfigured and severely impaired the plaintiff.

The lawsuit alleges that Magnevist is defective, and that the defendants failed to adequately test Magnevist and failed to warn patients about its potential to cause NSF.  The lawsuit further alleges that the chemical make-up of Magnevist makes it more likely that gadolinium will become free within the bodies of recipients, thereby making it more likely that kidney patients will develop NSF.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo